ArriVent BioPharma Inc.
AVBP | NASDAQ
$30.29
+$0.55 (+1.85%)
Sep 22, 2026, 1:45 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | -49.89M | -43.32M | -35.54M | -34.98M | -31.4M | -64.39M | -20.63M | -20.56M | -21.87M | -17.42M | -21.19M | -14.4M | -21.57M | -12.17M | -10.44M | -11.77M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 6.67M | 5.49M | 3.22M | 3.72M | 3.31M | 2.27M | 952K | 866K | 765K | 625K | 319K | 217K | 193K | 166K | 113K | 113K |
Other Working Capital | 18.08M | -6.31M | 4.7M | -6.41M | 2.27M | -6.47M | 4.39M | 2.52M | 2.37M | -1.46M | 5.67M | 972K | 9.07M | -4.5M | -5.58M | -466K |
Other Non-Cash Items | -7.92M | -559K | -3.03M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 11.57M | -3.5M | 4.69M | -4.54M | 1.96M | -5.89M | 3.53M | 3.35M | 2.02M | -1.84M | 5.96M | -1.26M | 12.77M | -4.88M | -5.56M | 1.73M |
Operating Cash Flow | -39.58M | -41.89M | -30.66M | -35.8M | -26.12M | -68.01M | -16.15M | -16.35M | -19.09M | -18.63M | -14.91M | -15.44M | -8.61M | -16.88M | -15.89M | -9.93M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -13.99M | -64.38M | -151.18M | -90.37M | -21.57M | -9.82M | -194.16M | n/a | n/a | n/a | n/a | n/a | -25M | n/a | n/a | n/a |
Sales Maturities Of Investments | 60.07M | 67.97M | 79.98M | 39.61M | 35.48M | 46.64M | n/a | n/a | n/a | n/a | 25M | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | 1.7M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | 46.07M | 3.58M | -71.2M | -50.76M | 13.91M | 36.82M | -192.47M | n/a | n/a | n/a | 25M | n/a | -25M | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | -70K | n/a | -227K | n/a | n/a | n/a | 44K | 1K | n/a | -1.03M | n/a | 26K | 15K | n/a |
Financial Cash Flow | 86.09M | 54.87M | 34.73M | 86.47M | 75.11M | 6.76M | 55K | 531K | 363K | 185.63M | -1.06M | -1.03M | -20K | 44.97M | 109.72M | n/a |
Net Cash Flow | 92.58M | 16.56M | -67.13M | -93K | 62.9M | -24.43M | -208.56M | -15.81M | -18.72M | 167M | 9.03M | -16.48M | -33.63M | 28.09M | 93.83M | -9.93M |
Free Cash Flow | -39.58M | -41.89M | -30.66M | -35.8M | -26.12M | -68.01M | -16.15M | -16.35M | -19.09M | -18.63M | -14.91M | -15.44M | -8.61M | -16.88M | -15.89M | -9.93M |
Adj. Free Cash Flow | -46.25M | -47.38M | -33.88M | -39.51M | -29.44M | -70.28M | -17.1M | -17.21M | -19.85M | -19.25M | -15.23M | -15.66M | -8.8M | -17.05M | -16M | -10.04M |
Maintenance CapEx | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Growth CapEx | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Owner Earnings | -39.58M | -41.89M | -30.66M | -35.8M | -26.12M | -68.01M | -16.15M | -16.35M | -19.09M | -18.63M | -14.91M | -15.44M | -8.61M | -16.88M | -15.89M | -9.93M |
Add to Watchlist
Select watchlists to add or remove AVBP